Home › Trial NCT00216073
Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer
- Trial IDNCT00216073
- StatusTerminated
- PhasePhase 2
- Study typeInterventional
- SponsorHoosier Cancer Research Network
- Enrollment11
- Start date2004-03
- ConditionsMetastatic Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.